SDARBODY Trademark

Trademark Overview

On Wednesday, July 1, 2020, a trademark application was filed for SDARBODY with the United States Patent and Trademark Office. The USPTO has given the SDARBODY trademark a serial number of 90031595. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, November 6, 2023. This trademark is owned by WuXi Biologics Co., Ltd.. The SDARBODY trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; drugs for medical purposes, namely, anticancer drugs; biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for veterinary purposes for treatment of canine disease; biological prepa...
sdarbody

General Information

Serial Number90031595
Word MarkSDARBODY
Filing DateWednesday, July 1, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, November 6, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 19, 2021

Trademark Statements

Goods and Servicespharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; drugs for medical purposes, namely, anticancer drugs; biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for veterinary purposes for treatment of canine disease; biological preparations for veterinary purposes for treatment of canine disease
Pseudo MarkSDAR BODY

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 30, 2020
Primary Code005
First Use Anywhere DateWednesday, November 30, 2022
First Use In Commerce DateWednesday, November 30, 2022

Trademark Owner History

Party NameWuXi Biologics Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressWuxi, Jiangsu 204092
CN
Party NameWuXi Biologics Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressWuxi, Jiangsu 204092
CN

Trademark Events

Event DateEvent Description
Monday, November 6, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, November 6, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, November 6, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, July 21, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 21, 2023NON-FINAL ACTION E-MAILED
Friday, July 21, 2023SU - NON-FINAL ACTION - WRITTEN
Wednesday, July 19, 2023STATEMENT OF USE PROCESSING COMPLETE
Tuesday, July 18, 2023USE AMENDMENT FILED
Tuesday, July 18, 2023TEAS STATEMENT OF USE RECEIVED
Friday, March 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 15, 2023SOU EXTENSION 4 GRANTED
Wednesday, March 15, 2023SOU EXTENSION 4 FILED
Wednesday, March 15, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 7, 2022SOU EXTENSION 3 GRANTED
Wednesday, September 7, 2022SOU EXTENSION 3 FILED
Wednesday, September 7, 2022SOU TEAS EXTENSION RECEIVED
Friday, February 18, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 16, 2022SOU EXTENSION 2 GRANTED
Wednesday, February 16, 2022SOU EXTENSION 2 FILED
Wednesday, February 16, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 7, 2021CORRECTED NOA E-MAILED
Wednesday, October 6, 2021SOU EXTENSION 1 GRANTED
Monday, September 13, 2021SOU EXTENSION 1 FILED
Wednesday, October 6, 2021DIVISIONAL PROCESSING COMPLETE
Monday, September 13, 2021DIVISIONAL REQUEST RECEIVED
Monday, September 20, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 13, 2021TEAS REQUEST TO DIVIDE RECEIVED
Monday, September 13, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 16, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 19, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 19, 2021PUBLISHED FOR OPPOSITION
Wednesday, December 30, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 11, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 9, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 8, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 8, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Saturday, November 28, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, November 28, 2020FINAL REFUSAL E-MAILED
Saturday, November 28, 2020FINAL REFUSAL WRITTEN
Wednesday, October 21, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 20, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 20, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, September 27, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, September 27, 2020NON-FINAL ACTION E-MAILED
Sunday, September 27, 2020NON-FINAL ACTION WRITTEN
Sunday, September 13, 2020ASSIGNED TO EXAMINER
Thursday, July 30, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 4, 2020NEW APPLICATION ENTERED

Related Keywords

sdarbody disease treatment metabolic central cancer system nervous infectious purposes medicines